Cover Image
市場調查報告書

結核:開發中產品分析

Tuberculosis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232861
出版日期 內容資訊 英文 358 Pages
訂單完成後即時交付
價格
Back to Top
結核:開發中產品分析 Tuberculosis - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 358 Pages
簡介

結核病是可能透過淋巴節及血管擴展到全身器官的細菌感染疾病。常在肺中發病,症狀從無自覺(潛伏性結核)到活動期有全身性倦怠、咳嗽、排出混有出血的黏液、倦怠感、呼吸困難、體重減輕、胸部疼痛等症狀。

本報告提供結核的治療藥開發情形調查分析,提供開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

結核概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9340IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tuberculosis - Pipeline Review, H1 2017, provides an overview of the Tuberculosis (Infectious Disease) pipeline landscape.

Tuberculosis, commonly known as TB, is a bacterial infection that can spread through the lymph nodes and bloodstream to any organ in body. It is most often found in the lungs. The symptoms of tuberculosis range from no symptoms (latent tuberculosis) to symptoms of active disease. Symptoms include overall sensation of feeling unwell; cough, possibly with bloody mucus, fatigue, shortness of breath, weight loss and pain in the chest.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tuberculosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tuberculosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tuberculosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tuberculosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 7, 8, 1, 60, 40 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 4, 4, 37 and 40 molecules, respectively.

Tuberculosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tuberculosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tuberculosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Tuberculosis - Overview
  • Tuberculosis - Therapeutics Development
  • Tuberculosis - Therapeutics Assessment
  • Tuberculosis - Companies Involved in Therapeutics Development
  • Tuberculosis - Drug Profiles
  • Tuberculosis - Dormant Projects
  • Tuberculosis - Discontinued Products
  • Tuberculosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Tuberculosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tuberculosis - Pipeline by Abera Bioscience AB, H1 2017
  • Tuberculosis - Pipeline by Anacor Pharmaceuticals Inc, H1 2017
  • Tuberculosis - Pipeline by Archivel Farma SL, H1 2017
  • Tuberculosis - Pipeline by AstraZeneca Plc, H1 2017
  • Tuberculosis - Pipeline by Beech Tree Labs Inc, H1 2017
  • Tuberculosis - Pipeline by BioDiem Ltd, H1 2017
  • Tuberculosis - Pipeline by BioLingus AG, H1 2017
  • Tuberculosis - Pipeline by Biomar Microbial Technologies, H1 2017
  • Tuberculosis - Pipeline by Bioversys AG, H1 2017
  • Tuberculosis - Pipeline by Celgene Corp, H1 2017
  • Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2017
  • Tuberculosis - Pipeline by Crestone Inc, H1 2017
  • Tuberculosis - Pipeline by Dafra Pharma International Ltd, H1 2017
  • Tuberculosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Tuberculosis - Pipeline by Demuris Ltd, H1 2017
  • Tuberculosis - Pipeline by Eisai Co Ltd, H1 2017
  • Tuberculosis - Pipeline by Eli Lilly and Company, H1 2017
  • Tuberculosis - Pipeline by Ensol Biosciences Inc, H1 2017
  • Tuberculosis - Pipeline by EpiVax Inc, H1 2017
  • Tuberculosis - Pipeline by Evotec AG, H1 2017
  • Tuberculosis - Pipeline by FIT Biotech Oy, H1 2017
  • Tuberculosis - Pipeline by GangaGen Inc, H1 2017
  • Tuberculosis - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Tuberculosis - Pipeline by Globeimmune Inc, H1 2017
  • Tuberculosis - Pipeline by Hager Biosciences LLC, H1 2017
  • Tuberculosis - Pipeline by Hsiri Therapeutics LLC, H1 2017
  • Tuberculosis - Pipeline by Imaxio SA, H1 2017
  • Tuberculosis - Pipeline by Immodulon Therapeutics Ltd, H1 2017
  • Tuberculosis - Pipeline by Immunitor Inc, H1 2017
  • Tuberculosis - Pipeline by ImmunoBiology Ltd, H1 2017
  • Tuberculosis - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Tuberculosis - Pipeline by Johnson & Johnson, H1 2017
  • Tuberculosis - Pipeline by Lakewood-Amedex Inc, H1 2017
  • Tuberculosis - Pipeline by LegoChem Biosciences Inc, H1 2017
  • Tuberculosis - Pipeline by Lipotek Pty Ltd, H1 2017
  • Tuberculosis - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Tuberculosis - Pipeline by Medivir AB, H1 2017
  • Tuberculosis - Pipeline by Merck & Co Inc, H1 2017
  • Tuberculosis - Pipeline by Microbion Corp, H1 2017
  • Tuberculosis - Pipeline by Microbiotix Inc, H1 2017
  • Tuberculosis - Pipeline by NEARMEDIC PLUS Ltd, H1 2017
  • Tuberculosis - Pipeline by Novartis AG, H1 2017
  • Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017
  • Tuberculosis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Tuberculosis - Pipeline by QureTech Bio AB, H1 2017
  • Tuberculosis - Pipeline by Qurient Co Ltd, H1 2017
  • Tuberculosis - Pipeline by Recce Ltd, H1 2017
  • Tuberculosis - Pipeline by Rodos BioTarget GmbH, H1 2017
  • Tuberculosis - Pipeline by Sanofi, H1 2017
  • Tuberculosis - Pipeline by Sanofi Pasteur SA, H1 2017
  • Tuberculosis - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Tuberculosis - Pipeline by Sequella Inc, H1 2017
  • Tuberculosis - Pipeline by Shionogi & Co Ltd, H1 2017
  • Tuberculosis - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
  • Tuberculosis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Tuberculosis - Pipeline by Theravectys SA, H1 2017
  • Tuberculosis - Pipeline by Tomegavax Inc, H1 2017
  • Tuberculosis - Pipeline by TVAX Biomedical Inc, H1 2017
  • Tuberculosis - Pipeline by Vaccibody AS, H1 2017
  • Tuberculosis - Pipeline by Vakzine Projekt Management GmbH, H1 2017
  • Tuberculosis - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2017
  • Tuberculosis - Pipeline by Vichem Chemie Research Ltd, H1 2017
  • Tuberculosis - Dormant Projects, H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Tuberculosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Tuberculosis - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Tuberculosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top